Terms: = Endocrine gland cancer AND RBM15, Q96T37, 64783, ENSG00000162775, OTT, OTT1 AND Prognosis
8 results:
1. rbm15‑mediating MDR1 mRNA m
Yuan J; Guan W; Li X; Wang F; Liu H; Xu G
Int J Oncol; 2023 Oct; 63(4):. PubMed ID: 37594126
[TBL] [Abstract] [Full Text] [Related]
2. Effect of the m6ARNA gene on the prognosis of thyroid cancer, immune infiltration, and promising immunotherapy.
Xia M; Wang S; Ye Y; Tu Y; Huang T; Gao L
Front Immunol; 2022; 13():995645. PubMed ID: 36389678
[TBL] [Abstract] [Full Text] [Related]
3. m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.
Zhang T; Sheng P; Jiang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2805-2822. PubMed ID: 35780396
[TBL] [Abstract] [Full Text] [Related]
4. Long noncoding RNA UBA6-AS1 inhibits the malignancy of ovarian cancer cells via suppressing the decay of UBA6 mRNA.
Wang Y; Chen Z
Bioengineered; 2022 Jan; 13(1):178-189. PubMed ID: 34951345
[TBL] [Abstract] [Full Text] [Related]
5. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract] [Full Text] [Related]
6. Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma.
Fu Y; Sun S; Bi J; Kong C; Yin L
Medicine (Baltimore); 2021 Mar; 100(10):e25031. PubMed ID: 33725886
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological and immunological characterization of RNA m
Wang Q; Zhang Q; Li Q; Zhang J; Zhang J
Mol Genet Genomic Med; 2021 Jan; 9(1):e1547. PubMed ID: 33225598
[TBL] [Abstract] [Full Text] [Related]
8. m
Hou J; Shan H; Zhang Y; Fan Y; Wu B
Am J Otolaryngol; 2020; 41(4):102547. PubMed ID: 32474328
[TBL] [Abstract] [Full Text] [Related]
